Endo, Bowing To FDA, Pulls Opana ER From Market

Endo Pharmaceuticals has announced that it will be pulling its Opana ER extended-release tablets from the market. Opana ER is an opioid agonist indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment.

It was determined by the Food and Drug Administration that the benefits of the drug did not outweigh its risks, which include opioid misuse and abuse. The drug was also tied to an HIV outbreak back in 2015, due to abuse of the drug via administration by needle injection. Debate continues to surround opioid drugs such as Opana . . .